Conditions: Psoriasis Immunomodulation
Keywords: Psoriasis PASI plaques skin biopsy immunomodulation
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 59
Healthy volunteers: no

Brief summary:
This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.

Detailed description:

Arms:
arm 1: 5 mg BID for 13 days and once on Day 14 arm 2: 10 mg BID for13 days and once on Day 14\* arm 3: 20 mg BID for 13 days and once on Day 14 arm 4: 30 mg BID for 13 days and once on Day 14 arm 5: 60 mg QD for 14 days arm 6: 50 mg BID x 13 days and once on day 14

Interventions: intervention 1: tofacitinib intervention 2: tofacitinib intervention 3: tofacitinib intervention 4: tofacitinib intervention 5: tofacitinib intervention 6: tofacitinib
Intervention descriptions: intervention 1: 5 mg BID For 13 days and once on Day 14 intervention 2: 10 mg BID for 13 days and once on Day 14\* intervention 3: 20 mg BID for 13 days and once on Day 14 intervention 4: 30 mg BID for 13 days and once on Day 14 intervention 5: 60 mg tablet once a day (QD) for 14 days intervention 6: 50 mg tablets two times a day (BID) for 13 days and once on day 14

Protocol document: